Maximum disease diameter is associated with outcomes in stage II follicular lymphoma treated with radiation therapy alone
40.7% of stage II FL patients treated with RT alone remained disease-free at 10 years. Greatest disease diameter >3.6 cm was associated with inferior FFP and OS, representing a novel prognostic indicator in this population that may help in the decision-making process on whether to complement RT with systemic therapy.
Authors
- Christopher P. Venner (ORCID: https://orcid.org/0000-0003-4701-4285)
- Alina S. Gerrie (ORCID: https://orcid.org/0000-0003-4727-1425)
- Yi Xu (ORCID: https://orcid.org/0000-0003-1235-3068)
- Pedro Farinha (ORCID: https://orcid.org/0000-0001-9364-9391)
- Kerry J. Savage (ORCID: https://orcid.org/0000-0002-5835-9863)
- David W. Scott (ORCID: https://orcid.org/0000-0002-0435-5947)
- Laurie H. Sehn (ORCID: https://orcid.org/0000-0003-1860-9765)
- Matthew Chan (ORCID: https://orcid.org/0000-0003-3510-9068)
- Diego R. Villa (ORCID: https://orcid.org/0000-0002-4625-3009)
- Belinda A. Campbell (ORCID: https://orcid.org/0000-0002-7316-8723)
- Andrea Lo (ORCID: https://orcid.org/0000-0002-3253-1071)
- Jessica Chan (ORCID: https://orcid.org/0000-0001-9104-118X)
Institutions
- BC Cancer Agency (CA)
- University of British Columbia (CA)
- The University of Melbourne (AU)
- Peter MacCallum Cancer Centre (AU)
- Spinal Cord Injury BC (CA)
Publication Details
- Journal
- Clinical and Translational Radiation Oncology
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.ctro.2024.100869
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Gilead Sciences
- Teva Pharmaceutical Industries
- Celgene
- F. Hoffmann-La Roche
- Regeneron Pharmaceuticals
- TG Therapeutics
- BeiGene
- Incyte
- Seagen
- BC Cancer Foundation
- Genentech
- Kite Pharma